Amsterdam UMC's Alzheimer Center Turns to a French Biomarker Lab for a Rare Proteomics Platform, More Than a Year After the Deal Was Signed

Standfirst

Stichting Amsterdam UMC has published the result of a fast tracked tender to analyse nearly 2 300 cerebrospinal fluid and blood plasma samples for its Alzheimer Center, awarding the work to Firalis Molecular Precision SA, a French contract research organisation and one of the few labs in Europe running the specialised Olink Explore HT proteomics platform. The notice, however, reports a contract that was actually signed back in March 2025 and contains two value figures that do not reconcile.

Introduction

Finding reliable biological signals for Alzheimer's disease before symptoms become severe is one of the more active frontiers in neurology research and it depends heavily on measuring proteins in blood and spinal fluid at a scale and precision that only a handful of specialised laboratories can deliver. Amsterdam UMC's Alzheimer Center, one of Europe's larger academic dementia research groups, needed exactly that kind of capacity for a batch of 600 cerebrospinal fluid samples and 1 634 plasma samples.

The resulting contract went to Firalis Molecular Precision SA, a French biomarker focused contract research organisation based near Basel, using a proteomics technology platform specific enough that it likely shaped who could realistically bid at all. The notice publishing that result surfaced only this week, though the underlying contract dates back to March 2025 and its numbers do not entirely add up.

Why This Contract Matters

Large scale protein biomarker analysis, known as proteomics, is central to current Alzheimer's research, helping scientists identify which proteins in blood or spinal fluid correlate with disease progression, a step toward earlier, less invasive diagnosis. A dataset spanning more than 2 200 samples processed on a single high throughput platform gives Amsterdam UMC's researchers a substantial, consistently generated resource for that work.

The procurement route matters too. Amsterdam UMC ran this as an accelerated open procedure, justified by a market consultation and a voluntary transparency notice that had already taken place beforehand. That combination typically signals a buyer that has already identified a very narrow, possibly single viable supplier before formally tendering, using the transparency notice to protect the award from legal challenge. For suppliers watching how hospitals and research centres buy specialised scientific services, that is a meaningful signal in itself.

Contract Timeline

• Prior market consultation referenced in the notice: TenderNed reference TN 501065
• Prior voluntary transparency notice referenced in the notice: TenderNed reference TN 504115
• Winner selected and contract concluded: 24 March 2025
• Notice dispatched to the Publications Office: 30 July 2026
• Published in the Official Journal, OJ S 146/2026: 31 July 2026

Contract Overview

Stichting Amsterdam UMC, the foundation behind Amsterdam's university medical centre, ran an accelerated open procedure for protein analysis of plasma and cerebrospinal fluid samples tied to its Alzheimer Center, described in the notice as covering 600 CSF samples and 1 634 plasma samples, to be carried out by a single operator. The main technical feature specified in the notice is analysis on the Olink Explore HT platform, a specific next generation proteomics technology. The contract runs for a compressed 64 day duration, structured as a single, one off service contract rather than a framework agreement.

Firalis Molecular Precision SA, based in Huningue in eastern France, won the contract as the sole named tenderer. The notice records the value of the winning tender at EUR 1 099 571, while separately stating that the value of all contracts awarded in this notice is EUR 12 277 356, a figure more than ten times larger. The contracting authority has not explained this gap and both figures are reported here as they appear in the notice rather than reconciled into one.

Key Contract Details

Project Scope

The contract covers protein analysis of 600 cerebrospinal fluid samples and 1 634 plasma samples for Amsterdam UMC's Alzheimer Center, to be carried out by a single supplier on the Olink Explore HT platform, a proteomics panel capable of measuring several thousand proteins from a very small sample volume. The notice states that the exact place of performance is unknown and depends on the winning supplier, reflecting the fact that this kind of specialised laboratory analysis is typically carried out at the supplier's own facility rather than on site at the buyer.

The tender's main features description names the Olink Explore HT platform specifically, rather than describing the required output in generic terms. That level of technical specificity narrows the realistic supplier field considerably, since relatively few contract research organisations in Europe operate this particular platform.

About the Contracting Authority

Stichting Amsterdam UMC is the foundation operating Amsterdam University Medical Center, a body governed by public law active in the health sector. It is based at De Boelelaan 1117 in Amsterdam, with its procurement contact listed as Marja Ramkema and a separate contact point for this specific tender, the Director of Strategic Procurement at Amsterdam UMC, represented by N. Laghrich Baaddi. The organisation's listed web address for this tender, vumc.nl, reflects Amsterdam UMC's origins in the merger of the Academic Medical Center and VU University Medical Center. Amsterdam UMC's Alzheimer Center is among the larger academic dementia research groups in Europe and this tender's biomarker analysis work sits within that centre's broader research programme.

About the Organisations Involved

Stichting Amsterdam UMC

As covered above, Stichting Amsterdam UMC is the buyer for this contract and, unusually, also fills every other organisational role disclosed in the notice: it is named as the organisation providing additional information about the procedure, the review organisation, the organisation providing information on review procedures, the mediation organisation and the organisation that signed the contract. No external review body, such as a court, is separately named.

Firalis Molecular Precision SA

Firalis Molecular Precision SA, the sole winner, is based in Huningue, in the Haut Rhin region of eastern France near the Swiss and German borders and is classified in the notice as a large enterprise. Independent company information describes Firalis Molecular Precision as a contract research organisation offering multi omics laboratory services, including proteomics, genomics and transcriptomics and states that the company became the first in France to offer the Olink Explore HT panel following its acquisition of the technology in late 2023. The same sources describe Firalis as an initiator of a large EU funded biomarker research consortium and note that the company joined a larger biosciences group in February 2026. This background is consistent with the tender's specific requirement for Olink Explore HT capability and helps explain why the field of eligible bidders for this contract was likely very narrow.

Procurement Analysis

Amsterdam UMC ran this as an accelerated open procedure, a route that shortens standard tendering deadlines. The justification given is that a market consultation and a voluntary transparency notice had already taken place before this tender was launched. A voluntary transparency notice is a mechanism EU buyers use to proactively publish an intended award, most often when they believe competition is genuinely limited to one or very few suppliers, in order to reduce the legal risk of a later challenge. Its presence here, alongside the highly specific Olink Explore HT technology requirement, points toward a procurement designed around a supplier field that was already understood to be narrow before the open procedure was launched.

Consistent with that reading, the award criteria disclosed in the notice consist of a single criterion, price, worth 100 percent of the score. Once the technical requirement effectively pre selects for labs running a specific, uncommon platform, price becomes the only meaningful variable left to evaluate.

Two aspects of the notice's own data do not fully reconcile and both are worth flagging plainly rather than resolved by assumption. First, the value of all contracts awarded in this notice is stated as EUR 12 277 356, more than ten times the EUR 1 099 571 recorded as the value of the single winning tender. Second, the statistical breakdown of received tenders shows 2 total tenders, but only 1 submitted electronically and 0 from an SME, an internal inconsistency the contracting authority has not clarified. Readers should treat both discrepancies as open questions rather than resolved facts.

Perhaps the most striking element of this notice is timing. The winner was selected and the contract concluded on 24 March 2025, yet this result notice was only dispatched to the Publications Office on 30 July 2026, publishing more than sixteen months after the contract was signed. EU transparency rules generally expect award notices to be published promptly after conclusion and a gap of this length is unusual, though the notice offers no explanation for the delay.

Additional Procurement Facts

• The contract is confirmed as covered by the Government Procurement Agreement and as not financed with EU funds.
• No strategic procurement aim, such as environmental or social criteria, is recorded for this lot.
• The winning tender is marked as not ranked and not a variant bid and subcontracting is marked as not applicable.
• No complaints were recorded against this contract.
• No framework agreement or dynamic purchasing system was used, confirming this as a single, standalone service contract.

Market and Industry Perspective

High throughput proteomics platforms like Olink Explore HT sit at a genuine capacity bottleneck in European biomarker research. Relatively few contract research organisations operate this specific technology and Firalis Molecular Precision's public marketing around being first in France to acquire the platform underscores how much of a differentiator that capability is in this market. For academic medical centres pursuing large scale biomarker studies, that scarcity shapes procurement outcomes well before a tender is published, often narrowing genuine competition to a small handful of specialised labs across the continent.

This dynamic is likely to intensify as more hospitals and research institutions pursue blood and CSF based biomarker studies for neurodegenerative disease, a fast growing area of clinical research. Labs that invest early in high throughput proteomics capacity are positioning themselves for a growing pipeline of similar institutional tenders across Europe.

Economic Significance

Whichever of the two disclosed values applies, this is a meaningful single service contract for a specialised laboratory analysis project rather than a routine institutional purchase. For Amsterdam UMC, the spending represents an investment in generating a substantial, harmonised biomarker dataset that can support multiple downstream research questions, extending the value of the contract well beyond its direct cost.

Future Procurement Opportunities

Given the pace of research interest in Alzheimer's biomarkers, Amsterdam UMC and comparable academic medical centres are likely to return to the market for further large scale proteomic or multi omics analysis work, particularly as biomarker panels expand and turnaround times improve. Suppliers with proven high throughput platform capacity, as demonstrated in this contract, are well positioned for that recurring demand.

Opportunities for Suppliers

Contract research organisations offering advanced proteomics, genomics or other multi omics laboratory services should treat this notice as confirmation that Dutch academic medical centres are actively commissioning specialised biomarker analysis work, often through accelerated procedures once a technical requirement narrows the field. Building and publicising specific platform capabilities, as Firalis Molecular Precision has done with Olink Explore HT, appears to be a meaningful differentiator in winning this kind of institutional research contract.

What Businesses Should Watch

• Whether Amsterdam UMC or other Dutch academic medical centres publish further tenders for large scale proteomic or biomarker analysis work.
• Whether the value discrepancy in this notice is corrected in a future change notice.
• The pace at which other contract research organisations acquire high throughput proteomics platforms comparable to Olink Explore HT, which could broaden the competitive field for similar future tenders.
• Publication timeliness on future Amsterdam UMC procurement notices, given the significant delay observed in this one.

NetherlandsTenders.com Procurement Intelligence

This notice illustrates how specialised scientific procurement often works in practice: a market consultation and voluntary transparency notice ahead of the formal tender, a highly specific technology requirement embedded in the scope and a price only evaluation once that requirement has done the real work of narrowing the field. For suppliers in specialised laboratory services, understanding this sequence matters more than reacting to the published tender itself, since by the time an accelerated procedure appears, the realistic competitive set may already be settled.

The unresolved figures in this notice, a value gap of more than ten times between the tender and notice totals and an internal mismatch in the tender count statistics, are also a reminder that award notices are administrative records compiled by busy procurement teams, not infallible datasets. Suppliers and market watchers using TED data for competitive intelligence should treat standout figures as worth verifying against other sources rather than as automatically definitive, particularly on notices covering highly specialised, narrow markets like this one.

Strategically, the sixteen month gap between contract signature and public disclosure is itself a data point worth watching. Whether it reflects an administrative backlog or something more specific to this contract, it is a reminder that TED notices sometimes report history rather than news and that procurement intelligence built solely on notice publication dates can lag the real state of a market by well over a year.

Supplier Takeaways

• This contract was awarded on price alone once a highly specific technology requirement, the Olink Explore HT platform, had already narrowed the field of realistic bidders.
• An accelerated procedure preceded by a market consultation and voluntary transparency notice often signals a buyer that already has a strong sense of which supplier can deliver.
• The notice contains an unresolved value discrepancy, EUR 1 099 571 for the winning tender against EUR 12 277 356 for the notice total, worth independently verifying if this contract is commercially relevant to you.
• The contract was actually signed in March 2025 but only publicly reported in July 2026, a reminder that public notice timing does not always reflect real time market activity.
• Investing early in scarce, specialised laboratory technology can be a decisive competitive advantage in institutional research procurement.

Key Takeaways

• Stichting Amsterdam UMC awarded a contract for proteomic analysis of 600 cerebrospinal fluid samples and 1 634 plasma samples for its Alzheimer Center to Firalis Molecular Precision SA, a French contract research organisation.
• The tender was run as an accelerated open procedure following a prior market consultation and voluntary transparency notice.
• Award criteria were 100 percent price, with the required Olink Explore HT technology platform effectively narrowing the field beforehand.
• The notice states two different value figures, EUR 1 099 571 for the winning tender and EUR 12 277 356 for the notice total, which are not reconciled.
• The contract was signed on 24 March 2025 but this result notice was only published on 31 July 2026, over sixteen months later.
• No complaints were recorded and the contract runs for a compressed 64 day duration.

Conclusion

Behind a short, technically dense notice sits a contract that says a great deal about how specialised scientific procurement actually works: a narrow field shaped well before the tender opens, a price only evaluation once that field is set and, in this case, a public disclosure that arrived well over a year after the ink dried. For Amsterdam UMC's Alzheimer Center, the result is a large, consistently generated biomarker dataset. For the wider market, it is a reminder that scarce technical capability, not competitive bidding, is often what really decides these contracts.

Source: Tenders Electronic Daily (TED), Contract Award Notice 530090 2026, Official Journal of the European Union, OJ S 146/2026, published on 31 July 2026.